The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD.

Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol. 2006; 24:3686-3692. Crossref. Scopus (128) ... 2021 Update ...

Figure 1.Bone marrow morphology, minimal residual disease (MRD), the timeline of treatment and efficacy evaluation. (A) Displays the bone marrow morphology at diagnosis, revealing myeloblasts ...

Of the 60%-70% of patients who achieve a CR with 7+3, approximately 40% achieve measurable residual disease–negative (MRD-negative) CR. 5,6,18,19 MRD assessment in AML is an important clinical tool ...

The upcoming webinar will delve into the advanced applications of Next Generation Flow™ in the analysis of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Dr. Juan Flores-Montero, a ...

Between 2008 and 2023, its oncology immunophenotyping lab saw the number of requests for flow cytometry increase from 3,000 to 8,500 per year, with samples of different types, which can add to the ...

Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML AML patients with diverse mutations, including TP53 ...

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress Provided by ...

The Company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid ...